Patent details

EP1871769 Title: CRYSTALLINE FORMS OF THE COMPOUND 4-(6-CHLORO-2,3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-1-YL)ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE.

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
EP1871769
WO Application Number:
GB2005004807
Type:
European Patent Granted for NL
Status:
Patent in Force
Publication Title:
Title When Made Available For Viewing:
Reason Lapsed:
Application number:
EP05818127.2
WO Publication Number:
WO2006064217
EPO Publication Language:
English
SPC Number:
First Applicant Residence Country:
Sweden (SE)
Publications:

Dates

Filing date:
14/12/2005
Grant date:
22/02/2017
EP Publication Date:
02/01/2008
WO Publication Date:
22/06/2006
Claims Translations Received Date:
Claims Translation B1 Received Date:
03/04/2017
Claims Translation B2 Received Date:
Claims Translation B3 Received Date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Published:
Due To Cession Date:
Registration date:
22/02/2017
EP B1 Publication Date:
22/02/2017
EP B2 Publication Date:
EP B3 Publication Date:
Description Translation B1 Received Date:
Description Translation B2 Received Date:
Description Translation B3 Received Date:
Expiration date:
13/12/2025
Lapsed By Expiration Date:
Revocation Date:
Invalidity Date:
Response To Novelty Search Report Received:
Patent Granting Request:
Lapsed date:

Applicant/holder

From:
22/02/2017
 
 

 

Name:
AstraZeneca AB
Address:
-, 151 85 SÖDERTÄLJE, Sweden (SE)

Domicile Holder

Name:
ir. W.J.J.M. Kempes
From:
03/04/2017
Address:
Dogio Patents Postbus 2350, 1200 CJ, Hilversum, Netherlands (NL)
To:

Inventor

1

Name:
FORD, James Gair AstraZeneca
Address:
Macclesfield Cheshire SK10 2NA, United Kingdom (GB)

2

Name:
MCCABE, James Francis AstraZeneca
Address:
Macclesfield Cheshire SK10 2NA, United Kingdom (GB)

3

Name:
O'KEARNEY-MCMULLAN, Anne AstraZeneca
Address:
Macclesfield Cheshire SK10 2NA, United Kingdom (GB)

4

Name:
O'KEEFE, Philip AstraZeneca R & D Charnwood
Address:
Loughborough Leicestershire LE11 5RH, United Kingdom (GB)

5

Name:
POINTON, Simon Mark AstraZeneca
Address:
Maccl esfield Cheshire SK10 2NA, United Kingdom (GB)

6

Name:
POWELL, Lyn AstraZeneca
Address:
Macclesfield Cheshire SK10 2NA, United Kingdom (GB)

7

Name:
PURDIE, Mark AstraZeneca R & D Charnwood
Address:
Loughborough Leicestershire LE11 5RH, United Kingdom (GB)

8

Name:
WITHNALL, Jane AstraZeneca R & D Charnwood
Address:
Loughborough Leicestershire LE11 5RH, United Kingdom (GB)

Priority

Priority Patent Number:
0427697
Priority Date:
17/12/2004
Priority Country:
United Kingdom (GB)

Classification

IPC or IDT classification:
A61K 31/517; C07D 405/12;

Publication

Bulletin

1

Bulletin Heading:
EP3
Journal edition number:
16/17
Publication date:
19/04/2017
Description:
European patents granted for the Netherlands in which a translation was filed ex Article 52 par. 1 of the NL Patent Law 1995

2

Bulletin Heading:
EP2
Journal edition number:
08/17
Publication date:
22/02/2017
Description:
European patents granted for the Netherlands

European Patent Bulletin

Issue number:
201708
Publication date:
22/02/2017
Description:
Grant (B1)

Annual Fee

Annual Fee(s) Due Date:
Annual Fee Number:
Last Annual Payment Date:
04/10/2024
Last Annual Fee Paid Number:
20
Last Annual Fee Paid Amount:
1400 Euro
Payer:
Computer Patent Annuities Limited (CPA)
Filing date Document type Document Description Number of pages File Type
13/04/2017 Outgoing Correspondence Letter no formal defects 1 PDF /7/6/5/1/3/0800131567/docs/ep05818127.2_1_130773l271.pdf
03/04/2017 Claims First filed claims 2 PDF /7/6/5/1/3/0800131567/docs/ep05818127.2_0_claims20170403133815680.pdf
03/04/2017 Incoming Correspondence Electronic Accompanying letter incoming document 2 PDF /7/6/5/1/3/0800131567/docs/ep05818127.2_2_incomingcorrespondenceelectronic20170403133817033.pdf